General Information
As of February 8, 2024
r/sellaslifesciences
sellaslifesciences
en
Gps P3 REGAL Trial Update: All pooled patients, best available therapy and Gps arms combined have an Overall Survival of 16 months. Current best available therapy os known to be 6-8 months, per Dr. Yair Levy the Dir of Hematological Research at Baylor Med. Gps Os 21 months in the Moffitt Center P2 - p value .02 ie 98% reproducibility. FDA Approval only requires 12.6 months of os per the new Sap. - not investment advice
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.
not investment advice.
490
March 9, 2021
public
N/A
Total Submissions
442
Total Comments
2,167
Earliest Submission
March 9, 2021
Earliest Comment
March 11, 2021
Metrics
Activity Over Time
Submission Flags
Comment Flags
Submission Score Distribution
Comment Score Distribution
Title Length
Submission Text Length
Comments per Submission
Most Distinctive Words
Rank↕ | Word↕ | Occurrences in Subreddit | Total Occurrences | Rate in Subreddit (per 1M words) | Rate in Reddit (per 1M words) | Ratio (Sub Rate / Reddit Rate) |
|---|---|---|---|---|---|---|
| #1 | 1,050 | 92,373 | 4363.4 | 0.8 | 5664.81 | |
| #2 | 295 | 30,108 | 1225.9 | 0.3 | 4882.94 | |
| #3 | 679 | 93,074 | 2821.6 | 0.8 | 3635.65 | |
| #4 | 125 | 23,884 | 519.4 | 0.2 | 2608.22 | |
| #5 | 193 | 43,443 | 802.0 | 0.4 | 2214.00 | |
| #6 | 258 | 59,726 | 1072.1 | 0.5 | 2152.77 | |
| #7 | 82 | 21,541 | 340.8 | 0.2 | 1897.09 | |
| #8 | 124 | 34,923 | 515.3 | 0.3 | 1769.50 | |
| #9 | 681 | 193,737 | 2830.0 | 1.6 | 1751.76 | |
| #10 | 169 | 51,406 | 702.3 | 0.4 | 1638.38 | |
| #11 | 91 | 34,519 | 378.2 | 0.3 | 1313.78 | |
| #12 | 58 | 22,783 | 241.0 | 0.2 | 1268.70 | |
| #13 | 129 | 57,052 | 536.1 | 0.5 | 1126.83 | |
| #14 | 1,653 | 733,014 | 6869.2 | 6.1 | 1123.83 | |
| #15 | commercialization commercialization | 46 | 20,475 | 191.2 | 0.2 | 1119.63 |
| #16 | 38 | 21,120 | 157.9 | 0.2 | 896.67 | |
| #17 | 83 | 49,630 | 344.9 | 0.4 | 833.44 | |
| #18 | 57 | 34,521 | 236.9 | 0.3 | 822.87 | |
| #19 | 35 | 22,829 | 145.4 | 0.2 | 764.05 | |
| #20 | 88 | 59,634 | 365.7 | 0.5 | 735.41 | |
| #21 | 276 | 187,562 | 1146.9 | 1.6 | 733.34 | |
| #22 | 81 | 60,931 | 336.6 | 0.5 | 662.50 | |
| #23 | 34 | 26,508 | 141.3 | 0.2 | 639.21 | |
| #24 | 333 | 279,447 | 1383.8 | 2.3 | 593.86 | |
| #25 | 34 | 31,380 | 141.3 | 0.3 | 539.97 | |
| #26 | 457 | 435,692 | 1899.1 | 3.6 | 522.73 | |
| #27 | 437 | 420,794 | 1816.0 | 3.5 | 517.55 | |
| #28 | 191 | 198,083 | 793.7 | 1.7 | 480.54 | |
| #29 | 46 | 48,963 | 191.2 | 0.4 | 468.20 | |
| #30 | 39 | 42,680 | 162.1 | 0.4 | 455.39 | |
| #31 | 183 | 204,448 | 760.5 | 1.7 | 446.08 | |
| #32 | 118 | 136,040 | 490.4 | 1.1 | 432.27 | |
| #33 | 198 | 231,875 | 822.8 | 1.9 | 425.55 | |
| #34 | 59 | 72,786 | 245.2 | 0.6 | 403.97 | |
| #35 | 1,865 | 2,323,847 | 7750.2 | 19.4 | 399.96 | |
| #36 | 31 | 41,297 | 128.8 | 0.3 | 374.10 | |
| #37 | 38 | 53,882 | 157.9 | 0.4 | 351.46 | |
| #38 | 92 | 131,787 | 382.3 | 1.1 | 347.90 | |
| #39 | 137 | 205,166 | 569.3 | 1.7 | 332.78 | |
| #40 | 32 | 48,946 | 133.0 | 0.4 | 325.82 | |
| #41 | 32 | 48,996 | 133.0 | 0.4 | 325.48 | |
| #42 | 81 | 124,626 | 336.6 | 1.0 | 323.90 | |
| #43 | 112 | 175,366 | 465.4 | 1.5 | 318.28 | |
| #44 | 42 | 67,018 | 174.5 | 0.6 | 312.32 | |
| #45 | 43 | 68,868 | 178.7 | 0.6 | 311.17 | |
| #46 | 46 | 77,344 | 191.2 | 0.6 | 296.40 | |
| #47 | 174 | 318,405 | 723.1 | 2.7 | 272.34 | |
| #48 | 166 | 303,882 | 689.8 | 2.5 | 272.24 | |
| #49 | 69 | 126,908 | 286.7 | 1.1 | 270.96 | |
| #50 | 115 | 218,888 | 477.9 | 1.8 | 261.83 |